PUBLISHER: DelveInsight | PRODUCT CODE: 1105492
PUBLISHER: DelveInsight | PRODUCT CODE: 1105492
DelveInsight's, "Severe Hypertriglyceridemia - Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Severe Hypertriglyceridemia Understanding
Severe Hypertriglyceridemia: Overview
Hypertriglyceridemia is a common condition, which is defined as having a high level (above 150 mg/dL) of triglycerides, a type of fat, in the bloodstream. Hypertriglyceridemia can lead to conditions including atherosclerosis (hardening of the arteries), obesity, and insulin resistance, which all can contribute to increased risk of cardiovascular disease (CVD). There are more than 2.1 million adults in the United States with severe hypertriglyceridemia (SHTG), which is defined as having a triglyceride level over 500 mg/dL. In addition to increasing the risk of CVD, SHTG is also a known risk factor for acute pancreatitis, a life-threatening condition. Risk factors for SHTG can include genetic disorders, obesity, untreated diabetes, and certain medications. While SHTG often causes no noticeable symptoms, individuals with extremely high levels of triglycerides (greater than 2,000 mg/dL) can experience recurrent abdominal pain, nausea, vomiting, xanthomas (yellow-colored bumps on the skin), and acute pancreatitis. There are many ways to prevent and treat SHTG. Lifestyle changes that can impact SHTG include lowering fat and carbohydrate intake, reducing alcohol consumption, and quitting smoking. For some people, lifestyle changes aren't enough to reduce triglycerides to the appropriate levels, leaving them at risk for additional complications. In these cases, there are pharmacological therapies that can reduce triglyceride levels to healthier levels
"Severe Hypertriglyceridemia - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Severe Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Severe Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Severe Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Severe Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Severe Hypertriglyceridemia Emerging Drugs Chapters
This segment of the Severe Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Severe Hypertriglyceridemia Emerging Drugs
ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. Currently, it is in Phase II stage of clinical trial evaluation to treat Severe Hypertriglyceridemia.
Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III in the liver. ApoC-III is a protein that regulates triglyceride metabolism in the blood by inhibiting lipoprotein lipase that breakdown triglycerides and by preventing clearance of triglyceride-rich lipoproteins. ApoC-III is an independent risk factor for both pancreatitis and cardiovascular disease.
Further product details are provided in the report……..
Severe Hypertriglyceridemia: Therapeutic Assessment
This segment of the report provides insights about the different Severe Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the therapies for Severe Hypertriglyceridemia. The companies which have their Severe Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, Ionis Pharmaceuticals, Inc.
DelveInsight's report covers around 10+ products under different phases of clinical development like
Severe Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Severe Hypertriglyceridemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Severe Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Hypertriglyceridemia drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Severe Hypertriglyceridemia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Severe Hypertriglyceridemia - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Olezarsen: Ionis Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ARO-APOC3: Arrowhead Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Severe Hypertriglyceridemia Key Companies
Severe Hypertriglyceridemia Key Products
Severe Hypertriglyceridemia- Unmet Needs
Severe Hypertriglyceridemia- Market Drivers and Barriers
Severe Hypertriglyceridemia- Future Perspectives and Conclusion
Severe Hypertriglyceridemia Analyst Views
Severe Hypertriglyceridemia Key Companies
Appendix